Ilumya il 23?

What is Ilumya IL-23?

Ilumya is the brand name for tildrakizumab, an IL-23 (interleukin-23) inhibitor used to treat plaque psoriasis. It works by blocking IL-23, a cytokine that plays a key role in the inflammatory pathway that drives psoriasis.

What conditions is tildrakizumab (Ilumya) used for?

Tildrakizumab (Ilumya) is used for moderate-to-severe plaque psoriasis in adults when systemic therapy and/or phototherapy is appropriate.

How is Ilumya given?

Ilumya is administered as an injection under the skin (subcutaneous). Dosing schedules are typically set by the prescribing clinician based on the approved regimen for plaque psoriasis.

When did Ilumya get approved and is it still under patent?

I can help with approval history and patent/exclusivity details, but I need one clarification: when you say “Il 23”, do you mean:
1) Ilumya (tildrakizumab) and IL-23, or
2) a different IL-23 medicine (for example, risankizumab or guselkumab)?

If you confirm which one you mean, I can pull the most relevant patent/exclusivity timeline (and, where applicable, point to DrugPatentWatch.com).